Trial
NCT04536077
Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
Celldex Therapeutics; The Foundation for Barnes-Jewish Hospital; National Cancer Institute (NCI)
Condition
Pancreatic Cancer
Intervention
CDX-301
Why stopped
Celldex decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-08